2023 cell and gene therapy industry survey

Stakeholders express positive outlook for cell and gene therapy market

Deloitte’s 2023 cell and gene therapy industry survey aimed to address the scarcity of CGT-specific information regarding past and future challenges across the value chain. The survey highlighted the key challenges and opportunities that organizations, their partners, and the broader cell and gene therapy market face.

When examining the sentiments expressed by stakeholders, CGT innovators and health care providers had a positive sentiment about the industry over the past 12–18 months. Approximately 86% of CGT innovators and 83% of health care providers felt that this period had been positive for CGTs. In contrast, only 66% of CDMOs shared the same sentiment.

However, in looking ahead to the next 12–18 months, there is a more positive outlook across all stakeholder groups. CGT innovators (93%), health care providers (86%), and CDMOs (83%) expressed optimism, believing that the future will bring positive developments for the industry. Respondents had a more favorable outlook for gene therapies than autologous and allogeneic cell therapies when considering the next 12–18 months.

Emerging opportunities in the cell and gene therapy market

Overall, responses tell a story of positive sentiment for the CGT industry, with most CGT leaders feeling positive about the past and expressing optimism for the future. However, differences emerged when considering specific therapy types, with gene therapies garnering the most positive outlook. While acknowledging the challenges ahead, the respondents expressed optimism about the potential of CGTs to transform health care and improve patient outcomes. The insights gathered from this survey highlight the challenges across various aspects of the CGT value chain, but also the collective industry sentiment about the potential of these therapies in the years to come.

By navigating the hurdles and capitalizing on emerging opportunities, the industry can continue to advance the development of these transformational treatments and the broader health care industry.

Get in touch